Clinical Trials
59 trialsTo Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
Shanghai Bovax Biotechnology Co., Ltd.
V503-064
Merck Sharp & Dohme LLC
FUTURE II
Merck Sharp & Dohme LLC
Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts
LEO Pharma
A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years
Shanghai Bovax Biotechnology Co., Ltd.
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
Shanghai Bovax Biotechnology Co., Ltd.
CARE-1
Verrica Pharmaceuticals Inc.
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
Merck Sharp & Dohme LLC
Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study
Integra LifeSciences Corporation
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
Shanghai Bovax Biotechnology Co., Ltd.
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
Shanghai Bovax Biotechnology Co., Ltd.
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
A Phase â…¢ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
Shanghai Zerun Biotechnology Co.,Ltd
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
Novan, Inc.
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
V503-053
Merck Sharp & Dohme LLC
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Beijing Health Guard Biotechnology, Inc
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
Shanghai Zerun Biotechnology Co.,Ltd
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts
Viatris Inc.
ING-HPV-1
SPP Pharmaclon Ltd.
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of External Genital Warts
ViroXis Corporation
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Novartis
V503-017
Merck Sharp & Dohme LLC
Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)
G&E Herbal Biotechnology Co., LTD
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
Merck Sharp & Dohme LLC
Safety and Efficacy of Laser Therapy in Gynaecology
Juna d.o.o.
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
Merck Sharp & Dohme LLC
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASILâ„¢ (V503-006)
Merck Sharp & Dohme LLC
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
Merck Sharp & Dohme LLC
GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
Merck Sharp & Dohme LLC
V501-020
Merck Sharp & Dohme LLC
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
Vaxart
Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)
Tamir Biotechnology, Inc.
Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts
Vaxart
Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts
Maruho Co., Ltd.
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
Merck Sharp & Dohme LLC
FUTURE
Merck Sharp & Dohme LLC
Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)
Merck Sharp & Dohme LLC
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
Merck Sharp & Dohme LLC
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
Merck Sharp & Dohme LLC
Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)
Merck Sharp & Dohme LLC
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
Merck Sharp & Dohme LLC
Recurrent and Nonrecurrent Condyloma Treatment
Laboratorio Elea Phoenix S.A.